PUFA Supplementation in Schizophrenia: A Placebo Controlled Study

Not Applicable

• Conditions: Health Condition 1: F20- Schizophrenia

• Registration Number: CTRI/2021/08/036019
• Lead Sponsor: central institute of psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Inclusion Criteria for Group 1 (supplement)

1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia.

2.Current positive symptoms rated �4 (moderate) on one or more of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behaviour, unusual thought content.

3.In an early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less.

4.Age 18 -50 years of both the sexes.

5.Having at least primary level of education.

6.Those who give informed consent for participating in the study.

Inclusion Criteria for Group 2 (placebo)

1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia

2.Age group of 18-50 years of both sexes.

3.In an early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less.

4.Having at least primary level of education.

5.Those who give informed consent for participating in the study.

Exclusion Criteria

Exclusion Criteria for Group 1 (supplement)

1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.

2.Pregnancy.

3.BMI > 30 kg/m2

4.Not willing to give written informed consent.

5.Any current systemic dyslipidaemia characterised by total cholesterol level �240 mg/dL, triglyceride level �150 mg/dL, low-density lipoprotein cholesterol level �140 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL.

Exclusion Criteria for Group 2 (placebo)

1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.

2.Pregnancy.

3.BMI > 30 kg/m 2

4.Not willing to give written informed consent.

5.Any current systemic dyslipidaemia characterised by total cholesterol level �240 mg/dL, triglyceride level �150 mg/dL, low-density lipoprotein cholesterol level �140 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL.

Study & Design

• Study Type: Interventional
• Study Design: Not specified